Biocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from acquiring Viatris Inc.’s biosimilars business. The company has already prepaid $250 million and is exploring ways to reduce finance costs. The bond’s rating will determine its pricing.
Sebi mulls allowing only electronic mode for payment of dividend, interest
Markets regulator Sebi on Friday proposed that listed entities should make all payments, such as dividends, interests and redemptions, through electronic mode only. The proposal